Evidence map›Paper›PMID 28163060›Full record

ReviewNeurochemistry international2017

An insight into the vision impairment following traumatic brain injury.

Nilkantha Sen

Open access · greenAbstract readReview
In one paragraph

Review in Neurochemistry international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Article
  6. VX-765 Alleviates Circadian Rhythm Disorder in a Rodent Model of Traumatic Brain Injury Plus Hemorrhagic Shock and Resuscitation.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2024
    Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Visual deficits after traumatic brain injury.Histology and histopathology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Nilkantha SenDepartment of Neuroscience and Regenerative Medicine, Augusta University, 1120 15th Street, CA 2018, Augusta, GA 30907, USA. Electronic address: nsen@augusta.edu.
Augusta University · US

Funding

Molecular Mechanisms underlying vision impairment after TBIR01EY025622 · NEI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SEN, NILKANTHA · 2016 to 2020
$1.9M
Development of therapeutic strategy against TBI based on hydrogen sulfideR01NS094516 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SEN, NILKANTHA · 2016 to 2020
$1.7M
NEI NIH HHS R01 EY025622NINDS NIH HHS R01 NS094516
6 · The paper itself

Abstract

Traumatic brain injury (TBI) is one of the major cause of morbidity and mortality and it affects more than 1.7 million Americans each year. Depending on its location and severity, TBI leads to structural and functional damage in several parts of the brain such as cranial nerves, optic nerve tract or other circuitry involved in vision, and occipital lobe. As a result, the function associated with vision processing and perception are significantly affected and cause blurred vision, double vision, decreased peripheral vision and blindness. In this mini-review, we will focus the recent progress made to understand the pathology and underlying cellular/molecular mechanisms involved in the impairment of the integrity of visual systems following TBI.

Indexed as

AnimalsBrainBrain Injuries, TraumaticCognitionHumansOptic NerveOptic Nerve InjuriesVision, Ocular

Identifiers

PMID28163060
PMCPMC5540824
OpenAlexW2585318016

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.